Skip to content
Close
Customers
Biopharma
MedTech
Payers & Providers
Government
Products
Software Overview
Discover
Substantiate
Data Powered Offerings
Generate
Services
Regulatory & Scientific Services
Data Services
Company
About Us
Regulatory Partnerships
Leadership
Careers
Resources
News
Evidence Hub
Events
CARE Initiative
SEARCH
Let's Talk
Customers
Biopharma
MedTech
Payers & Providers
Government
Products
Software Overview
Discover
Substantiate
Data Powered Offerings
Generate
Services
Regulatory & Scientific Services
Data Services
Company
About Us
Regulatory Partnerships
Leadership
Careers
Resources
News
Evidence Hub
Events
CARE Initiative
Let's Talk
Quick results for "{search_term}"
Admin
Jun 9, 2017
< 1 min read
Class of diabetes drug raises risk for diabetic ketoacidosis
Previous
Next
A study published in the New England Journal of Medicine suggests that a new class of type 2 diabetes drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, may increase the risk of diabetic ketoacidosis.
Read More
Admin
RELATED ARTICLES
